(EW) Edwards Lifesciences - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082
EW: Heart Valves, Surgical Systems, Monitoring Systems
Edwards Lifesciences is a leader in medical devices, specializing in structural heart disease and critical care monitoring. Their innovation in transcatheter heart valves stands out, offering minimally invasive solutions that transform patient care. Products like the Edwards SAPIEN system and PASCAL technology exemplify their commitment to advancing cardiac treatment.
Financially, Edwards boasts a robust revenue stream, supported by strong gross margins and significant R&D investments. Their market cap of $41.5 billion underscores their prominence, with a P/E ratio suggesting growth potential. This financial health is crucial for investors seeking stability and growth.
With a global footprint and direct sales force, Edwards market reach is extensive, mitigating risks through diversification. Their focus on innovation and customer-centric approach positions them as resilient in a competitive landscape, making them a compelling choice for fund managers.
Additional Sources for EW Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EW Stock Overview
| Market Cap in USD | 40,944m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2000-03-27 |
EW Stock Ratings
| Growth Rating | -20.5 |
| Fundamental | 57.8 |
| Dividend Rating | 0.0 |
| Rel. Strength | -16.8 |
| Analysts | 3.7/5 |
| Fair Price Momentum | 64.65 USD |
| Fair Price DCF | 10.88 USD |
EW Dividends
No Dividends PaidEW Growth Ratios
| Growth Correlation 3m | -19.1% |
| Growth Correlation 12m | -33.3% |
| Growth Correlation 5y | -37.9% |
| CAGR 5y | -0.91% |
| CAGR/Max DD 5y | -0.02 |
| Sharpe Ratio 12m | -0.32 |
| Alpha | -22.72 |
| Beta | 0.500 |
| Volatility | 31.07% |
| Current Volume | 0k |
| Average Volume 20d | 4702k |
As of April 19, 2025, the stock is trading at USD 71.53 with a total of 0 shares traded.
Over the past week, the price has changed by +3.07%, over one month by +1.69%, over three months by +2.23% and over the past year by -17.26%.
Partly, yes. Based on ValueRay Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 57.82 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EW as of April 2025 is 64.65. This means that EW is currently overvalued and has a potential downside of -9.62%.
Edwards Lifesciences has received a consensus analysts rating of 3.70. Therefor, it is recommend to hold EW.
- Strong Buy: 9
- Buy: 5
- Hold: 19
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, EW Edwards Lifesciences will be worth about 70.5 in April 2026. The stock is currently trading at 71.53. This means that the stock has a potential downside of -1.43%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 80.2 | 12.1% |
| Analysts Target Price | 79.6 | 11.2% |
| ValueRay Target Price | 70.5 | -1.4% |